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Background: Hypoglycemia is a common complication of diabetes treatment. This paper describes symptoms,
predecessors, consequences and medications associated with the first episode of severe hypoglycemia among
ACCORD participants with type 2 diabetes, and compares these between intensive (Int: goal A1C <6.0%) and
standard (Std, goal A1C 7–7.9%) glycemia intervention groups.
Methods: Information about symptoms, antecedents, and consequences was collected at the time participants
reported an episode of severe hypoglycemia. Data on medications prescribed during the clinical trial was used to
determine the association of particular diabetes drug classes and severe hypoglycemia.
Results: The most frequently reported symptoms in both glycemia group were weakness/fatigue (Int 29%; Std
30%) and sweating (Int 26%; Std 27%), followed by confusion/disorientation (Int 22%; Std 29%) and shakiness (Int
21%; Std 19%). Approximately half of all events were preceded by a variation in food intake (Int 48%; Std 58%). The
most common consequences were confusion (Int 37%; Std 34%), loss of consciousness (Int 25%; Std 25%), and
hospitalization (Int 18%; Std 24%). The highest rates of hypoglycemia were found among those participants treated
with insulin only (Int 6.09/100 person yrs; Std 2.64/100 person yrs) while the lowest were among those prescribed
oral agents only (Int 1.93/100 person yrs; Std 0.20/100 person yrs).
Conclusions: Severe hypoglycemia episodes were frequently preceded by a change in food intake, making many
episodes potentially preventable. Symptoms of confusion/disorientation and loss of consciousness were frequently
seen. The highest rates of hypoglycemia were seen with prescription of insulin, either alone or in combination with
other medications.
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Hypoglycemia is a common complication associated
with treatment of diabetes [1]. Often mild, in its more
severe forms hypoglycemia can cause seizures, coma,
and even death. Although hypoglycemia occurs more
frequently in patients with type 1 as compared to type 2
diabetes [1], clinicians often see more hypoglycemia in
patients with type 2 diabetes simply because of the high
prevalence of disease. One study that used a restrictive
definition of hypoglycemia (requiring medical assistance)
found similar rates for both type 1 and type 2 diabetes
[2]. Indeed, the rising number of patients with type 2
diabetes in the United States and the focus on tighter
glucose control for these patients has resulted in an in-
crease in the number of hypoglycemic [3] reports in this
group.
The most common causes of hypoglycemia among
patients with type 2 diabetes include the use of
hypoglycemic medications [4], inadequate caloric intake,
exercise, errors with use of medications, and intercur-
rent illnesses. A better understanding of the association
of these various variables with hypoglycemia would as-
sist in counseling patients to manage and prevent this
complication. The Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study offers a unique op-
portunity to examine the immediate predecessors to se-
vere hypoglycemic events. As part of routine safety
monitoring of study participants, extensive reporting of
the immediate predecessors and consequences of severe
hypoglycemia were systematically captured. In addition,
a comprehensive list of prescribed glycemia medications
was kept.
The purpose of this paper is to describe the symptoms
reported by ACCORD subjects who experienced severe
hypoglycemia requiring medical assistance (HMA).
Comparisons between glycemia intervention study
groups (intensive strategy including a goal A1C< 6%
versus standard strategy including goal A1C 7–7.9%) are
made for predecessors and consequences to determine if
there are differences by study group. Furthermore, com-
parisons between those with and without a reported epi-
sode of HMA are made for medication usage to
determine if prescription of a particular class of medica-
tion or prescriptions of combination of medications is
associated with severe hypoglycemia.
Methods
The ACCORD Study is a double 2x2 factorial trial
designed to test the effect of an intensive glucose control
strategy defined as a goal hemoglobin A1C ≤ 6.0%, versus
a standard control strategy (goal hemoglobin A1C be-
tween 7.0 and 7.9%), intensive blood pressure control
strategy (SBP< 120 mmHg) versus standard control
strategy (SBP< 140 mmHg), and a lipid treatmentstrategy that utilizes fenofibrate plus a statin, compared
to one that uses a statin alone, on the composite out-
come of myocardial infarction, stroke or cardiovascular
death [5]. The intensive glycemia intervention was
stopped early due to increased mortality in this group,
and all participants were transitioned to the standard
glycemia intervention for the remainder of the trial. This
analysis is limited to the period of time prior to this
transition. Main results have been previously reported
[6-8], as has a full description of the methodology and
the rationale for the trial [5,9]. All clinical sites obtain
Institutional Review Board approval for the ACCORD
Study.
Study participants and design
Briefly, participants were eligible to enroll in ACCORD
if they had type 2 diabetes, a hemoglobin A1C of 7.5-
11%, and were either between the ages of 40 and
79 years with cardiovascular disease, or between the
ages of 55 and 79 years with evidence of significant
atherosclerosis, albuminuria, left ventricular hyper-
trophy, or two or more additional risk factors for car-
diovascular disease (dyslipidemia, hypertension, current
smoker, or obesity). Participants also needed to meet
inclusion criteria for blood pressure and/or lipid trials.
Participants were excluded if they had a history of fre-
quent or recent serious hypoglycemic events, history
of coma/seizure within the last 12 months, unwilling-
ness to do home glucose monitoring or inject insulin,
a body-mass index (the weight in kilograms divided by
the square of the height in meters) of more than
45 kg/m2, a serum creatinine level of more than
1.5 mg per deciliter (133 μmol per liter), or other ser-
ious illness.
Participants were randomly assigned to intensive or
standard glycemia intervention strategy. All participants
received education and counseling about diabetes care.
Supplies for glucose monitoring and glucose-lowering
medications (from a study-supervised formulary of FDA-
approved medications) were provided. Glucose lowering
medications not on the ACCORD formulary could be
prescribed to participants but were not provided free of
cost to participants. Medications were utilized at the dis-
cretion of the study physician, with a suggested algo-
rithm of order of use provided in the protocol. Use of
medication class was not limited by study assignment.
Intensive group participants were expected to be seen
and medications adjusted every 2 months with at least
one phone contact between visits while standard group
participants were expected to be seen every 4 months
(or more frequently as needed). Self-monitoring of blood
glucose (SMBG) was advised for participants in both
groups with more frequent monitoring recommended
for intensive group participants and less frequent for
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included diabetes clinics, primary care clinics and dedi-
cated research clinics. For this report, we used data for
all follow-up contacts where ACCORD physicians ac-
tively managed the participant’s glycemia medications
through February 5, 2008, the date that participants were
notified that intensive glycemia participants were to be
transitioned to standard glycemia therapy.Definition and reporting of hypoglycemia
Participants were asked at every visit if they had
experienced episodes of low blood sugar. A full de-
scription of the review of such events, including the
adjustment of therapeutic goals in response to severe
hypoglycemia, has been previously reported [10]. The
present report focuses on symptomatic, severe hy-
poglycemic events requiring medical assistance
(hospitalization, visit to the emergency room, treatment
by medical personnel including emergency medical
technician either in a clinical setting or at home) which
was defined in ACCORD as either a blood glucose less
than 50 mg/dl (2.8 mmol/L) or symptoms that
promptly resolved with oral carbohydrate, intravenous
glucose, or glucagon. NOTE: Prior to March 2003,
clinic sites were not required to document the blood
glucose level of the participant during a hypoglycemic
episode requiring medical assistance. Fifteen percent of
the episodes used in the analyses in this paper do not
have this documentation. Exclusion of events without
this documentation does not qualitatively change the
conclusions. (Data not shown.)
Following a report of a severe hypoglycemic episode
by the participant, research staff inquired about the cir-
cumstances surrounding the episode. Standardized
forms that utilized lists, check boxes and free text boxes
were used to collect information. The time of the event
(4 hour intervals check boxes) and whether the event
had occurred while the participant was asleep was col-
lected. Symptoms that the participant experienced prior
to treatment of the hypoglycemia were ascertained and
recorded. Symptom choices included both physical
symptoms (e.g., shakiness, fast heartbeat) as well as psy-
chological (e.g., anxiety) and neuroglycopenic (e.g., con-
fusion). More than one symptom could be reported.
Activities and circumstances immediately antecedent
to and consequences of the event were also obtained.
Antecedents included changes in diet and exercise,
changes in both glucose lowering medications and other
medications, and intercurrent illnesses. Potential conse-
quences included physiological responses (loss of con-
sciousness, seizure), emergency treatment, and accident
or injury. For both antecedents and consequences, more
than one response was possible.Medications
Prescribed medications were recorded at each study
visit. Oral glucose lowering medications were documen-
ted with both the dose and frequency prescribed at the
time of the study visit. Insulin was noted on a separate
management sheet. For both oral glucose- lowering
medications and insulin, the type and dose of the medi-
cation reported by the participant at the beginning of
the study visit and changes made in the regimen at the
study visit were recorded. For this analysis, participants
are assumed to be taking the prescribed medications at
the time of the hypoglycemic episode if the medication
was prescribed at the exit from the study visit just prior
to the reported severe hypoglycemia event. Although the
ACCORD protocol did not limit the type of glucose-low-
ering medication that could be used in the study, this
analysis focuses on those medications most commonly
used among the ACCORD participants. For analysis,
medications are also combined based on mechanism of
action (insulin sensitizer =TZD, metformin; basal insu-
lin =NPH, lente, ultralente, glargine, insulin pump, dete-
mir; bolus insulin = regular, aspart, lispro, glulisine;
premixed = 70/30, 75/25, 50/50). Medication prescription
was categorized for each period of follow-up in terms of
use of: just oral agents alone, just insulin alone, oral
agents and insulin combined, or no glycemia medica-
tions. Additionally, the number of different medications
was categorized as 0 or 1, 2, or 3+ within each follow-up
interval by calculating the number of the following med-
ications prescribed: sulfonlyureas, biguanides, thiazolidi-
nediones (TZD), alpha glucosidase inhibitors (AGIs),
meglitinides, incretins, bolus insulin, basal insulin, and
premixed insulin. For this analysis, we used all medica-
tion information until the time of the initial
hypoglycemia event or until the final visit when partici-
pants had their glycemia medications actively managed
by ACCORD physicians.
Statistical analysis
All statistical analyses were conducted at the coordinat-
ing center with the use of SAS software, version 9.2
(SAS Institute). All analyses were conducted on the first
reported hypoglycemic event requiring medical assist-
ance (HMA). Symptoms reported at the time of the
event and immediate antecedents to events are summar-
ized as the number and percent of all initial events.
Use of glucose-lowering medications was summarized
according to study group as the total person-years that
participants were prescribed medications. Person-years
were determined by using clinic reports of what was
prescribed for the interval of time between each clinic
visit. Rates of HMA per 100 person-years of medication
use was obtained by taking the number of initial events
that occurred while participants were prescribed a
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of use.
Hazard ratios (95% CI) relating the risk of HMA to
prescription of medications were obtained within gly-
cemia treatment groups using Cox proportional
hazards (PH) regression models allowing for medica-
tion use as time-dependent covariates and controlling
for the baseline covariates identified in Miller et al.
[11] as predictive of future episodes of severe
hypoglycemia. These baseline covariates included: age,
gender, race, education, BMI, history of neuropathy/
nerve problems, time since diagnosis of diabetes, A1C,
albumin to creatinine ratio, serum creatinine, LDL-C,
as well as factors used to stratify randomization (treat-
ment groups within the BP and Lipid trials and the
presence of clinical cardiovascular disease). Series of
models that were fitted included baseline covariates
plus each of the following as a single additional factor
entered into the model: 1) each medication; 2) the
oral/insulin medication category variables; 3) the num-
ber of medications. In addition to these models, we fit-
ted models with all medications in the model and
a priori selected the following interactions to investigate:
oral agents and insulin, insulin and insulin sensitizers;
metformin, sulfonylurea and TZDs; insulin, sulfony-




Documented blood glucose <50 mg/dl 63% (344)
Event occurred while participant was asleep 18% (101)
Reported symptoms at the time of event
Weakness/Fatigue 29% (160)
Sweating 26% (144)
Confused or Disoriented 22% (123)
Shakiness 21% (116)
Dizziness 16% (86)
Blurry Vision 9% (49)
Anxious 10% (57)
Irritable 8% (44)




12:01 am - 4 am 10% (40)
4:01 am - 8 am 12% (47)
8:01 am - 12 pm 23% (91)
12:01 pm - 4 pm 21% (86)
4:01 pm - 8 pm 20% (81)
8:01 pm - 12 am 14% (58)Results
A total of 732 first time severe hypoglycemic events
were reported by ACCORD participants. Three times
more events occurred among participants in the inten-
sive group (N= 547) than those in the standard group
(N= 185). There were no differences by study group in
the percentage of participants with severe hypoglycemia
who had documented blood glucose less than 50 mg/dl
or who reported the occurrence of the event while
asleep (see Table 1). Similarly, there were no difference
in the reported symptoms by study group with the most
frequent being symptoms of weakness/fatigue, sweating,
and confusion/disorientation and shakiness. Episodes
tended to occur less frequently at night than during the
day. In addition, episodes among participants in the
standard group tended to occur with increased fre-
quency between 12 AM and 12 PM while participants in
the intensive group had more episodes between 12 PM
and 12 AM.
The most frequently listed antecedents to a severe
hypoglycemic episode can be characterized as behav-
ioral. Approximately half of all severe hypoglycemic epi-
sodes were preceded by a food related incident (either a
delayed or missed meal or had less carbohydrate con-
sumption than anticipated), with a higher percentage of

























Bonds et al. BMC Endocrine Disorders 2012, 12:5 Page 5 of 9
http://www.biomedcentral.com/1472-6823/12/5group reporting food related antecedents (see Table 2).
Unexpected or more vigorous exercise than usual for
the participant was also a relatively common antecedent
but did not vary by study group. Incorrect medication
dosage and intercurrent illness were relatively uncom-
mon antecedents.
Emergency room visits, treatment by EMTs and hospi-
talizations were all common but likely due to the defin-
ition of severe hypoglycemia used in this analysis.
Approximately one third of the episodes were associated
with confusion or irrational behavior (see Table 2), and
one quarter resulted in a loss of consciousness. There
were 45 reported personal accidents or injuries, includ-
ing 3 reports of fractures, 5 participants with lacerations,
and 5 motor vehicle accidents with no difference by
study group.
Participants in both glycemia groups who were treated
with only oral medications had a lower rate of
hypoglycemic episodes than those on insulin alone or in-
sulin plus oral agents (Table 3). The rate of hypoglycemiaTable 2 Comparison by glycemia intervention group of repor
hypoglycemia(1)
Immediate antecedents to severe hypoglycemic event:
None
Food Related
Delayed or missed meal
Ate less carbohydrate than prescribed or usual at preceding meal or snac
Ingested alcohol
Exercised unexpectedly or more vigorously than usual
Took incorrect type and dose of insulin (e.g. aspart instead of glargine at hs)
Took more insulin than prescribed or usually administered
Took more sulfonylurea or meglitinide than prescribed
Started on new medication known to cause hypoglycemia or to mask sympt
Experienced recent weight loss without appropriate adjustment of insulin do
Has an intercurrent illness as a cause without an error in exercise/food/drugs
Cognitive impairment/decline
Other
Immediate consequences of severe hypoglycemia event
None
ER visit or seen by EMT (without hospitalization)
Confusion/irrational behavior
Coma/loss of consciousness with no seizure
Hospitalization
Personal Accident or injury
Seizure
Injury to another individual
Other
(1) Only collected on events occurring after August 2003.was highest in those on insulin alone in both groups, aver-
aging about 6 episodes for every 100 person-years in the
intensive group and almost 3 episodes per 100 person-
years in the standard group. Those participants treated
with insulin plus oral medication had a rate of
hypoglycemia that was between those treated with only
oral agents and those treated with insulin alone, 3.31 to
3.69 per 100 person years in the intensive and 1.60-1.85
per 100 person years in the standard group.
Determination of the risk of experiencing a hypo-
glycemic event by different categorizations of medica-
tions (see Table 4) revealed a lower risk of hypoglycemia
among those treated with oral agents only compared to
those treated with insulin only (INT adjHR 0.53, 95%CI
0.36-0.78; STD adjHR 0.13, 95%CI 0.08-0.24). No differ-
ence was seen among those treated with oral agent and
insulin compared to insulin alone. Within the intensive
glycemia participants, few differences were seen with the
addition of a sensitizer to insulin, or sulfonylurea to met-








14% (79) 11% (20) 0.21
48% (263) 58% (107) 0.02
31% (167) 44% (81) <.01
k 26% (144) 25% (47) 0.81
3% (18) 2% (4) 0.44
15% (80) 12% (23) 0.46
1% (8) 2% (4) 0.52
5% (30) 7% (13) 0.44
1% (7) 2% (3) 0.73
oms 2% (10) 8% (14) <.01
se 3% (15) 3% (6) 0.72
4% (22) 3% (6) 0.63
6% (33) 11% (20) 0.03
23% (124) 24% (45) 0.64
3% (17) 1% (1) 0.05
67% (364) 75% (138) 0.04
37% (203) 34% (62) 0.38
25% (137) 25% (47) 0.92
18% (99) 24% (44) 0.09
6% (33) 6% (12) 0.82
2% (10) 3% (6) 0.26
1% (3) 1% (1) 0.99
6% (35) 8% (14) 0.58
Table 3 Association of hypoglycemic events with glycemia medication class(1)
Intensive Glycemia Standard Glycemia
Medication class Person yrs of
use of medication
or combination









# of HMA events
associated
medication use
# events per 100
Person yrs
All Cases 17141.4 547 3.19 17709.9 185 1.04
Combination of medication classes
Oral medication only(2) 5691.6 110 1.93 9202.7 18 0.20
Metformin, TZD(3) 10342.1 300 2.90 5179.3 46 0.89
Metformin, Sulfonylurea, TZD(4) 6073.3 165 2.72 3360.7 18 0.54
Insulin only(5) 705.6 43 6.09 1476.6 39 2.64
Insulin plus metformin 8853.8 293 3.31 5116.1 82 1.60
Insulin plus insulin sensitizer(6) 10271.5 379 3.69 5991.6 111 1.85
Insulin plus secretagogue(7) 6747.5 226 3.35 3609.0 59 1.63
(1) participant reported a hypoglycemic event while taking the medication.
(2) any combination of oral medications but no insulin.
(3) metformin + TZD, regardless of other medications.
(4) metformin + TZD + sulfonylurea, regardless of other medications.
(5) any combination of insulin but no oral medications.
(6) insulin sensitizer = TZD, metformin.
(7) insulin secretogogues = sulfonylurea, meglitinides (prandin), incretins (exenatide).
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of HMA than those prescribed no sensitizer or only a
sensitizer. In the intensive group, there was no difference
in risk of hypoglycemia by number of medications while
a higher risk with 3 or more medications was seen in the
standard group.
Determination of the hazard ratio for use of each class
of medication (see Tables 5 and 6), found that the lowest
risk was for those given a prescription of a biguanide
compared to those that were not prescribed this medica-
tion (INT adjHR 0.78, 95%CI 0.63-0.96; STD adjHR 0.73
95%CI 0.53-1.00) and that the highest risk was among
those prescribed a TZD (INT adjHR 1.62, 95%CI 1.33-Table 4 Adjusted hazard ratio (HR) of severe hypoglycemia b
Medication Use in Interval Antecedent to Ascertainment of Event Statu
Just Oral Agents vs. Just Insulin
Oral Agents plus Insulin vs. Just Insulin
No Glycemia Medication(2) vs. Just Insulin
Insulin plus Sensitizer vs. Just Insulin(3)
No Insulin or Sensitizer(4) vs. Just Insulin(3)
Just Sensitizer vs. Just Insulin(3)
Metformin + Sulfonlyurea + TZD vs. Metformin + TZD(5)
2 meds vs. 0 or 1 meds
3 meds vs. 0 or 1 meds
(1) All results control for the following baseline covariates: age, gender, race, educat
A1C, albumin to creatinine ratio, serum creatinine, LDL-C, and factors used to stratif
presence of clinical cardiovascular disease)
(2) In the standard group, there were 430 person years out of a total of 17,698 perso
of a total of 17,130 person years (0.2%) in which participants were on no glycemia
(3) Model also controls for use of AGI’s, meglitinide, incretins and sulfonylurea.
(4) Participants in this group were prescribed sulfonylureas, AGI, meglitinide, incretin
(5) Model also controls for use of Insulin, AGI’s, meglitinide, incretins and sulfonylure1.99; STD adjHR 1.83 95%CI 1.35-2.48) and those pre-
scribed insulin (see Tables 5 and 6 for hazard ratios).
Further exploration of the increased risk among those
prescribed a TZD found that the highest rate of events
was among those participants treated with insulin plus a
TZD but not with a sulfonylurea plus a TZD in both the
intensive group (4.48 events per 100 person-years) and
the standard group (3.42 events per 100 person-years)
(see appendix material).
Discussion
Our analysis of hypoglycemic events in the ACCORD
trial shows that a large portion of events are precededy combination of classes(1)
s Intensive Standard
HR 95% CI P value HR 95% CI P value
0.53 (0.36, 0.78) <.0001 0.13 (0.08, 0.24) <.0001
0.93 (0.67, 1.31) 0.69 0.97 (0.66, 1.43) 0.89
1.47 (0.35, 6.1) 0.60 0.15 (0.02, 1.09) 0.06
1.19 (0.88, 1.61) 0.25 0.98 (0.69, 1.40) 0.93
1.32 (0.56, 3.11) 0.52 0.22 (0.08, 0.62) <.0001
0.66 (0.45, 0.94) 0.02 0.14 (0.07, 0.25) <.0001
0.94 (0.72, 1.23) 0.65 0.60 (0.32, 1.11) 0.10
0.83 (0.46, 1.5) 0.53 1.08 (0.64, 1.82) 0.78
1.04 (0.59, 1.82) 0.89 1.82 (1.10, 3.00) 0.02
ion, time since diabetes diagnosis, history of neuropathy/nerve problems, BMI,
y randomization (treatment groups within the BP and Lipid trials and the




Table 5 Unadjusted and adjusted HR of severe hypoglycemia by medication class - Intensive group participants(1)
Medication Use in Interval Antecedent to
Ascertainment of Event Status
Unadjusted Adjusted(2)
HR 95% CI P value HR 95% CI P value
Sulfonylurea 0.87 (0.73, 1.04) 0.12 1.06 (0.88, 1.28) 0.54
Biguanide 0.73 (0.59, 0.89) <.0001 0.78 (0.63, 0.96) 0.02
TZDs 1.40 (1.15, 1.70) <.0001 1.62 (1.33, 1.99) <.0001
AGIs 1.05 (0.71, 1.54) 0.81 1.10 (0.74, 1.62) 0.64
Meglitinide 0.91 (0.74, 1.12) 0.37 1.10 (0.88, 1.38) 0.38
Incretin 0.97 (0.51, 1.82) 0.92 1.06 (0.56, 1.99) 0.86
Bolus Insulin 1.62 (1.35, 1.95) <.0001 1.58 (1.26, 1.98) <.0001
Basal Insulin 1.61 (1.30, 1.99) <.0001 1.44 (1.13, 1.85) <.0001
Pre-Mixed Insulin 1.41 (0.94, 2.13) 0.10 1.91 (1.25, 2.92) <.0001
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modifiable or preventable. Over half of all hypoglycemia
episodes in both the standard and intensive group were
related to either delaying or missing a meal or eating less
food than normal. Additional behaviors that preceded
hypoglycemic events included increased physical activity
and incorrect medication use although incorrect medica-
tion use was listed as an antecedent (1-8% depending on
medication) much less frequently than diet related beha-
viors. At the time of reporting severe hypoglycemic
events, participants and staff were also asked about
changes in medications that were not used to treat dia-
betes but known to either lower blood glucose or mask
the symptoms of low blood glucose (e.g. beta blockers or
ACE inhibitors). While there was differential reporting
of these as antecedents between the intensive interven-
tional study group (2%) and the standard interventional
study group (8%), overall, this was infrequently listed as
an antecedent in comparison to behavioral factors.
The consequences of severe hypoglycemia were fre-
quently clinically significant. A large number of the
hypoglycemic events reported in this paper resulted in
hospitalization. This is in part due to the definition of se-
vere hypoglycemia used in the ACCORD study (low blood
glucose and treatment by medical personnel). Importantly,
approximately 25% of the severe hypoglycemic incidents
reported by the ACCORD participants resulted in loss of
consciousness, about a third in confusion/irrational behav-
ior, and 6% resulted in a personal accident or injury. Also
of note, and perhaps associated with the more severe
complications, the frequency of the neuroglycopenic
symptoms of confusion/disorientation was equal to the
adrenergic sweaty and shaky symptoms [12]. This combin-
ation of potentially dangerous consequences combined
with the high frequency of preventable antecedents illus-
trates the importance of appropriate education of patients
with diabetes on techniques to prevent hypoglycemia.
More events occurred among those who were pre-
scribed insulin. This finding has been reported in other
papers [13,14]. This may be due to the action of insulinor due to the clinical characteristics of participants for
whom insulin is prescribed or both. ACCORD was a
clinical trial testing strategies for glycemic control and a
variety of medications were available for use to obtain
the target A1Cs in each arm of the trial. The recom-
mended study algorithm of treatments suggested the use
of oral medications before addition of insulin. Thus, par-
ticipants who were prescribed insulin may have repre-
sented those participants whose disease was more
difficult to control. They may also represent participants
who had contraindications, such as impaired renal func-
tion, to some oral agents.
As expected, we found a low rate of severe
hypoglycemic events associated with the biguanide class.
This has also been reported in other papers [13,15]. In
contrast, we unexpectedly found high rates of hy-
poglycemia among those participants treated with TZD.
Few participants were prescribed TZDs alone so we can-
not determine the rate among those who used this medi-
cation alone. When we examined the use of TZD in
conjunction with sulfonylureas and insulin (two of the
most commonly used medications in ACCORD), we
found the highest rates of hypoglycemia among those
who were prescribed TZDs in combination with insulin
as compared to the combination of TZD with sulfony-
lureas. Among those participants who were prescribed
TZD but not sulfonylurea or insulin, the incidence rate
of severe hypoglycemia was similar to that reported in a
prescription monitoring program [16]. Although the
mechanism for this finding is not clear, it is possible that
the insulin sensitizing action of the TZD accentuates the
risk of hypoglycemia of insulin when these two are used
in combination. Alternatively, rosiglitizone has been
shown to preserve [17] and possibly improve pancreatic
beta cells function [18]. This preservation/improvement
in the responsiveness of the beta cells in combination
with exogenous insulin and improved insulin sensitivity
could lead to increased risk of hypoglycemia.
There are several strengths to this analysis. We collected
a large amount of data about symptoms, antecedents, and
Table 6 Unadjusted and adjusted HR of severe hypoglycemia by medication class - Standard group participants(1)
Medication Use in Interval Antecedent
to Ascertainment of Event Status
Unadjusted Adjusted(2)
HR 95% CI P value HR 95% CI P value
Sulfonylurea 0.51 (0.37, 0.69) <.0001 0.85 (0.6, 1.20) 0.36
Biguanide 0.54 (0.40, 0.74) <.0001 0.73 (0.53, 1.00) 0.05
TZDs 1.47 (1.09, 1.98) 0.01 1.83 (1.35, 2.48) <.0001
AGIs 1.48 (0.54, 4.01) 0.44 1.45 (0.52, 4.03) 0.48
Meglitinide 1.34 (0.85, 2.10) 0.21 1.50 (0.93, 2.42) 0.10
Incretin 1.84 (0.58, 5.86) 0.30 1.80 (0.56, 5.74) 0.32
Bolus Insulin 2.25 (1.63, 3.09) <.0001 1.68 (1.14, 2.47) 0.01
Basal Insulin 2.72 (1.95, 3.79) <.0001 0.85 (0.60, 1.20) 0.36
Pre-Mixed Insulin 2.24 (1.56, 3.23) <.0001 0.73 (0.53, 1.00) 0.05
(1) Hazard ratio for use of medication as part of glycemia medication regimen compared to participants who were not prescribed medication. All results control
for the following baseline covariates: age, gender, race, education, time since diabetes diagnosis, history of neuropathy/nerve problems, BMI, A1C, albumin to
creatinine ratio, serum creatinine, LDL-C, and factors used to stratify randomization (treatment groups within the BP and Lipid trials and the presence of clinical
cardiovascular disease).
(2) Adjusted for baseline covariates and other listed glycemia medications.
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we did not obtain similar information in those participants
that did not experience hypoglycemia and cannot deter-
mine the risk of hypoglycemia with the various antece-
dents. ACCORD had a large study population and used a
number of common diabetes medications allowing us to
examine the rate of hypoglycemia in a variety of medica-
tions and combinations. However, the study tested strat-
egies, and participants were not randomly assigned to
particular medications. Thus, this analysis can only pro-
vide associations. We focused on first events in this paper;
when we conducted similar analysis on symptoms, antece-
dents and consequences of the second reported severe
hypoglycemic event, we found no significant difference
between study arms.
There are some limitations that should be discussed.
There is considerable confounding between participant
characteristics and the prescription of certain medica-
tions. While we have attempted to account for this in
our analysis, it is likely there is still some residual con-
founding. ACCORD did not capture actual medication
use. This analysis instead utilizes prescription of medica-
tion. It is possible that some medications prescribed
were not actually taken by the study participant.
Symptoms, antecedents and consequences of the
hypoglycemic events rely to some degree on patient
self-report and thus may be subject to under or over-
reporting.Conclusion
What potential beneficial actions might these data sug-
gest? Confusion and loss of consciousness was often
seen as consequences of severe hypoglycemia. These ser-
ious outcomes suggest the need for clinicians to help
their patients develop a proactive plan for prevention
which includes recognition of symptoms such asconfusion or disorientation as potential signs of
hypoglycemia. While ACCORD was not designed to
evaluate preventative measures, we did find lower overall
rates of hypoglycemia in the standard group. The more
frequent use of oral medications in the standard group
suggests that these medications should be considered in
those experiencing severe hypoglycemia. The biguanide
class of medication had the lowest risk of hypoglycemia;
adjustment of medication toward biguanides where pos-
sible is an option to consider.
Perhaps the most important finding from these ana-
lyses is that over half of hypoglycemic episodes were
preceded by a decrease in carbohydrate intake. With
proactive planning by patients with diabetes, this behav-
ior could be changed with a potentially large impact on
the risk of severe hypoglycemia. Adding these potential
tools into already existing algorithms for preventing se-
vere hypoglycemic episodes, could provide the patient
and clinician more choices for shared decision making
to avoid severe events.
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